# Precigen, Inc > Clarifo company profile — qualitative business description generated from > the company's filings. Financial statements, charts and ratios are > available on Clarifo (https://www.clarifo.com/en/companies/Precigen, Inc). ## Overview Precigen, Inc. is a U.S.-based biopharmaceutical company focused on precision medicines and platform-enabled product development for difficult-to-treat diseases. Its business combines proprietary technology platforms, clinical-stage therapeutic programs, and the Exemplar subsidiary, which develops and sells genetically engineered miniature swine models. ## Products & services • Papzimeos gene therapy for recurrent respiratory papillomatosis • Proprietary precision medicine and gene therapy platforms • Exemplar miniature swine models for research use • Collaboration and licensing arrangements for platform assets • Development services tied to engineered animal models - **Therapeutic product candidates** (5%) — Clinical and commercial-stage precision medicine programs, including Papzimeos. - **Research models** (90%) — Genetically engineered miniature swine models sold through Exemplar. - **Collaboration and licensing** (5%) — Revenue from strategic agreements, cancellations, or modifications of prior deals. - Papzimeos gene therapy for recurrent respiratory papillomatosis - Proprietary precision medicine and gene therapy platforms - Exemplar miniature swine models for research use - Collaboration and licensing arrangements for platform assets - Development services tied to engineered animal models ## Customers Precigen sells to research, translational, and commercial customers that need specialized animal models or access to its biotechnology platforms. Its therapeutic business is aimed at patients through healthcare providers and, ultimately, payers and treatment centers once products are commercialized. Collaboration revenue, when present, comes from pharmaceutical or biotechnology partners that license or access platform assets. - **Research institutions and laboratories** (primary) — Buy Exemplar miniature swine models for preclinical research and translational studies. - **Biopharma collaboration partners** (secondary) — Enter licensing or strategic agreements around proprietary platforms and programs. - **Healthcare providers and specialty clinics** (emerging) — Would use Papzimeos in the commercial setting for recurrent respiratory papillomatosis. - **Patients with high-unmet-need diseases** (emerging) — The end beneficiaries of the company’s therapeutic programs, especially rare diseases. - Academic and translational researchers buying miniature swine models - Biotech and pharma partners licensing platform technologies - Healthcare providers and treatment centers for future Papzimeos use - Patients with rare or difficult-to-treat diseases - Commercial and preclinical users needing engineered research models ## Geography Precigen is headquartered in the United States and its reported business activity is centered there. The company’s research, development, and commercial execution are tied to U.S. regulatory and market access pathways, while Exemplar and platform collaborations may extend to external partners outside the U.S. No country-level revenue breakdown was disclosed in the provided excerpts. - Headquartered and primarily operated in the United States - U.S. FDA pathway is central for Papzimeos commercialization - Exemplar sales and services are reported from U.S.-based operations - Collaboration activity may involve partners outside the United States - No country-level revenue disclosure was provided in the excerpts ## Strategy Precigen is prioritizing the transition from a platform-development company toward a commercial-stage biopharmaceutical business. The core strategic focus is to launch Papzimeos, advance proprietary programs, and use platform assets to create additional product and collaboration opportunities. Exemplar remains a current revenue source while the company builds a broader therapeutic portfolio. - **Launch and commercialize Papzimeos** (short-term) — A successful launch would shift the company toward recurring product sales and validate the platform. - **Advance proprietary pipeline programs** (medium-term) — Pipeline progression is needed to diversify revenue beyond Exemplar and collaborations. - **Monetize platform assets through partnerships** (medium-term) — Collaborations can provide non-dilutive capital and external validation of the technology base. - Commercialize Papzimeos and build a product revenue base - Advance proprietary programs from proof-of-concept to market - Use technology platforms to generate additional pipeline assets - Maintain Exemplar as a source of product and service revenue - Pursue strategic transactions and collaborations for non-core assets ## Risks Precigen faces the typical risks of a development-stage biopharmaceutical company: regulatory uncertainty, clinical and manufacturing execution risk, and dependence on future product launches. The company also has material financing and leverage risk, plus impairment risk tied to goodwill, intangible assets, and strategic transactions involving its operating units. - **Regulatory and commercialization risk for Papzimeos** [high] — Revenue depends on successful approval, launch, and market adoption of a new gene therapy. - **Going-concern and financing risk** [critical] — The company may need additional capital if commercialization and other revenues do not scale as planned. - **Debt and covenant risk** [high] — Senior secured term debt adds mandatory interest, principal amortization, and restrictive covenants. - **Impairment risk for goodwill and intangible assets** [medium] — Strategic changes or weaker fair value assumptions could trigger non-cash impairment charges. - **Development-stage biotech execution risk** [high] — Clinical, manufacturing, and scale-up activities can be delayed or cost more than expected. - Papzimeos commercialization depends on regulatory and launch execution - Clinical development programs may fail, delay, or require more capital - Debt service and covenant compliance restrict financial flexibility - Goodwill and intangible assets may be impaired if assumptions weaken - Collaboration revenue can be volatile and dependent on deal activity ## Accounting Revenue recognition is split between point-in-time product sales, service revenue from Exemplar, and collaboration/licensing revenue that can be recognized on contract changes or terminations. Investors should also watch goodwill and intangible asset impairment testing, because management explicitly notes that changes in assumptions or strategic transactions could trigger charges. Lease obligations, R&D commitments, and milestone/royalty arrangements add judgment to future cash flow and expense recognition. - **Revenue recognition** — Product sales, services, and collaboration revenue - **Goodwill and intangible asset impairment** — Non-cash operating expense and equity - **Milestone and royalty arrangements** — Future cash obligations and expense recognition - **Lease accounting** — Balance sheet and liquidity analysis - **R&D commitments** — Cash burn and expense visibility - Product revenue is recognized when control transfers to the customer - Service revenue from Exemplar depends on delivery of model-related services - Collaboration revenue may be recognized on cancellation or modification events - Goodwill and intangible assets require impairment testing and fair value judgment - Milestone and royalty obligations affect future expense and cash flow timing - Operating leases and R&D commitments create fixed future obligations --- *Last updated: 2026-09-24T12:28:50.038746+00:00*